Traditional LMM deal sourcing relies on broad broker networks and auction participation, leading to margin compression. This pitch pivots toward a thesis-driven, outbound origination model targeting highly fragmented, asset-light B2B service sectors. By leveraging top-tier strategic due diligence frameworks (L.E.K. methodologies), we computationally map the New England market to engage founder-owned targets before they hit the broader market.
Laboratory and medical equipment calibration is mission-critical, asset-light, and regulatory-driven. Hospitals, biopharma labs, and CROs are aggressively outsourcing maintenance to Independent Service Organizations (ISOs) to convert fixed headcount into variable OpEx. Highly fragmented with sticky, recurring revenue via multi-year MSAs.
Greater Boston is the densest life sciences and biopharma hub globally (Kendall Square, Longwood, Seaport). The sheer volume of lab space in MA, RI, and CT creates an unusually deep regional TAM. A Boston-based bank has a geographic moat to roll up local ISOs into a regional powerhouse.
At L.E.K. Boston, my core focus was MedTech PE due diligence. I understand FDA/ISO compliance pathways and hospital procurement dynamics. I don't just pull Capital IQ lists; I build proprietary market maps of regional ISOs, evaluate their service contracts like a PE buyer, and speak the operational language of clinical founders.
Regulatory tailwinds (USP <797> and <800>) require compounding pharmacies and sterile environments to undergo continuous certification. High specialized knowledge requirement but low capital intensity (the asset is the certified workforce). Ripe for geographic roll-ups.
Boston's biomanufacturing footprint is expanding rapidly outward (Waltham, Lexington) and into RI/NH. New England has a dense network of regional healthcare systems requiring mandatory compliance testing. Easy local canvassing for MDs.
This sector sits perfectly at the intersection of my MedTech and Industrials background. I know how to underwrite regulatory-driven TAMs and analyze operational bottlenecks. I can screen targets based on certification tiers, effectively completing preliminary commercial due diligence before the engagement letter is signed.
Labor shortages force legacy manufacturers to automate. They hire System Integrators (SIs) to design/install robotics. SIs are highly asset-light (pure consulting/software). Fragmented industry with boomer-aged engineer-founders lacking succession plans.
New England has a dual identity: a massive legacy manufacturing base (aerospace in CT, machining in MA/NH) and a world-class robotics hub (Route 128, MIT spin-offs). Perfect for brokering deals between legacy buyers and tech capabilities.
My Industrials casework focused heavily on OEMs and Industry 4.0. When pitching founders, I discuss backlog, utilization rates, and OEM vendor relationships (Fanuc, Rockwell) rather than just EBITDA. This builds instant credibility with technical founders who typically distrust bankers.